

AIMD-based Therapies of Heart Failure

Heart failure, which affects an estimated 64 million people worldwide, is a condition in which the heart weakens to the point that it cannot pump sufficient oxygen-rich blood to meet the body's needs. Patients with heart failure experience debilitating symptoms which significantly diminish their quality of life.

Today, most heart failure patients are prescribed medications intended to slow the progression of the disease and manage their symptoms, but which provide limited or no improvement to the heart's pumping ability.

This talk will describe new implantable device-based therapies that have emerged to address the heart's insufficient capacity, and which are demonstrating significant improvements in quality of life, and even reversion in the disease state.



David Prutchi received the Ph.D. in Biomedical Engineering from Tel-Aviv University. He conducted post-doctoral research at Washington University in St. Louis, after which he worked at Sulzer-Intermedics developing the company's next-generation cardiac pacing platform. In 1998 he joined Impulse Dynamics, to lead the development of active implantable devices for the treatment of heart failure through cardiac contractility modulation. He is currently Impulse Dynamics' Chief Technology Officer and Executive Vice-President.